OGN interim CEO Morrissey awarded 131,233 Organon RSUs, vesting through 2028

Rhea-AI Filing Summary

Organon & Co. reported an equity grant to its interim CEO. On November 13, 2025, officer and interim CEO Joseph T. Morrissey, Jr. received 131,233 restricted stock units (RSUs), each convertible into one share of Organon common stock. The RSUs were granted following the company’s earnings release for the quarter ended September 30, 2025. These RSUs vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028. After this grant, Morrissey beneficially owns 131,233 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrissey Joseph T. Jr.

(Last) (First) (Middle)

C/O ORGANON & CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NJ 07302

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/13/2025		A		131,233		(2)	(2)	Common Stock	131,233	$0	131,233	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") converts into one share of Organon & Co. ("Organon") common stock.

2. The Reporting Person was granted RSUs on November 13, 2025 (which was the close of business on the third business day following the release of Organon's earnings for the quarter ended September 30, 2025, on November 10, 2025). These RSUs vest and become exercisable in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Faye C. Brown, as Attorney-in-Fact for Joseph T. Morrissey, Jr.	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Organon (OGN) report in this Form 4?

Organon & Co. reported that interim CEO and officer Joseph T. Morrissey, Jr. received a grant of 131,233 restricted stock units (RSUs) on November 13, 2025.

How many Organon (OGN) RSUs were granted to the interim CEO?

The interim CEO was granted 131,233 restricted stock units (RSUs), each RSU converting into one share of Organon common stock.

When do the newly granted Organon (OGN) RSUs vest?

The RSUs vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.

What does each Organon (OGN) RSU convert into for the interim CEO grant?

Each restricted stock unit (RSU) converts into one share of Organon & Co. common stock.

How many derivative securities does the Organon (OGN) interim CEO own after this transaction?

Following the reported grant, interim CEO Joseph T. Morrissey, Jr. beneficially owns 131,233 derivative securities, held directly.

What was the context for the timing of the Organon (OGN) RSU grant?

The RSUs were granted on November 13, 2025, which was the close of business on the third business day after Organon’s earnings release for the quarter ended September 30, 2025.